Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Pant Pushes for De-Escalated Options, Targeted Therapy in Pancreatic Cancer

March 11th 2020

Shubham Pant, MD, discusses frontline treatment selection in metastatic pancreatic cancer and shed light on some of the latest research being done in the space.

FDA Approves Nivolumab/Ipilimumab for Advanced HCC

March 11th 2020

The FDA has granted an accelerated approval to the combination of nivolumab and ipilimumab for the treatment of patients with hepatocellular carcinoma who have received prior therapy with sorafenib.

Dr. Musher on Current Therapies for HCC

March 11th 2020

Benjamin Leon Musher, MD, discusses the current treatment options for patients with hepatocellular carcinoma.

Dr. Overman on Investigational Targeted Therapies in mCRC

March 11th 2020

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses investigational targeted therapies in metastatic colorectal cancer (mCRC).

Early-Stage Pancreatic Cancer Paradigm Needs Refining

March 10th 2020

Matthew H.G. Katz, MD, FACS, discusses data with neoadjuvant therapy and ongoing research in pancreatic cancer.

Advancing the mCRC Paradigm With Clinical Trials and Molecular Profiling

March 10th 2020

Kanwal Raghav, MBBS, MD, discusses the implications of molecular profiling on treatment decisions in metastatic colorectal cancer and the importance of referring patients to clinical trials.

Dr. Pant on Immunotherapy Combos and Upcoming Developments in Pancreatic Cancer

March 10th 2020

Shubham Pant, MD, discusses combination immunotherapies and upcoming developments in pancreatic cancer.

Integrating Immunotherapy Into HCC Treatment Paradigm

March 10th 2020

Ahmed O. Kaseb, MD, discusses important considerations in the frontline treatment of patients with advanced hepatocellular carcinoma, the potential for targeted therapy in the space, and ongoing research with immunotherapy in earlier stages of disease.

Sequencing Challenges, Novel Research Efforts Come to Forefront in HCC

March 9th 2020

Benjamin Leon Musher, MD, discusses sequencing challenges and research efforts needed regarding immunotherapy in hepatocellular carcinoma before it becomes a standard approach for patients.

Navigating NGS and Novel Therapies in GI Malignancies in New York

March 6th 2020

We recently traveled to Brooklyn, New York, for a State of the Science Summit™ on Gastrointestinal Cancer, which featured insights from Weill Cornell Medical Center and Montefiore Medical Center faculty.

Dr. Charlton on the Emergence of Biomarkers in HCC

March 5th 2020

Michael R. Charlton, MD, MBBS, discusses the emergence of biomarkers in hepatocellular carcinoma.

Research in mCRC Underscores Importance of Individualized Approach

March 5th 2020

Michael J. Overman, MD, discusses the current treatment landscape of metastatic colorectal cancer and ongoing research efforts in the space.

FDA Grants Breakthrough Device Status to Elecsys GALAD Score for HCC

March 4th 2020

The FDA has granted a breakthrough device designation to the Elecsys GALAD score, an algorithmic score designed to aid in the diagnosis of early-stage hepatocellular carcinoma.

Dr. Khan on Retrospective Analysis of Demographics in CRC and Gastric Cancer

March 4th 2020

Amir Khan, MD, discusses a large retrospective database analysis on colorectal cancer and gastric cancer presented at the 2020 Gastrointestinal Cancers Symposium.

Dr. Katz on Preoperative Chemotherapy in Resectable Pancreatic Cancer

March 4th 2020

Matthew H.G. Katz, MD, FACS, discusses the utility of preoperative chemotherapy for patients with resectable pancreatic cancer.

Dana-Farber Tackles Rising Incidence of Young-Onset Colorectal Cancer

March 3rd 2020

Dana-Farber Cancer Institute launched the Young-Onset Colorectal Cancer Center, among the first of its kind, in March 2019 to provide expert and compassionate clinical care, promote scientific discovery and innovation to elucidate underlying biological mechanisms, identify risk factors, and facilitate development of novel therapies, and improve prevention and early detection by raising public awareness of the rising burden of CRC in young adults.

Biomarkers, Patient Factors Inform HCC Treatment Decisions Beyond Frontline Setting

March 3rd 2020

There are clear biomarkers available to guide treatment decisions in the second-line setting for patients with advanced hepatocellular carcinoma, Lipika Goyal, MD, Mphil, said during a presentation at the 2020 HCC-TAG Conference.

Dr. Chung on the Effect of Combo Therapies in Patients With Pancreatic Cancer

March 3rd 2020

Vincent Chung, MD, discusses the effect of gemcitabine, nab-paclitaxel (Abraxane), metformin, and dietary supplements on patients with pancreatic cancer.

Dr. Raghav on Activating the RAS/RAF/MEK/ERK Pathway in CRC

March 3rd 2020

Kanwal Raghav, MBBS, MD, discusses the activation of the RAS/RAF/MET/ERK pathway in colorectal cancer.

El-Khoueiry Forecasts Future of HCC Treatment Paradigm

March 3rd 2020

By 2025, Anthony El-Khoueiry, MD, expects to see a larger menu of approved drugs and drug combinations for the treatment of advanced hepatocellular carcinoma, better use of molecular and immune signatures to guide treatment decisions, and, possibly, the chance to cure intermediate- and advanced-stage disease.